InMode Ltd. (NASDAQ:INMD) Stock Holdings Lessened by DDD Partners LLC

DDD Partners LLC lessened its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 46.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 606,965 shares of the healthcare company’s stock after selling 522,863 shares during the period. DDD Partners LLC owned 0.72% of InMode worth $10,136,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its holdings in shares of InMode by 314.7% during the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock valued at $60,000 after purchasing an additional 2,694 shares during the last quarter. Quarry LP increased its position in InMode by 154.3% in the third quarter. Quarry LP now owns 3,781 shares of the healthcare company’s stock worth $64,000 after buying an additional 2,294 shares during the period. National Bank of Canada FI lifted its stake in InMode by 6.2% in the third quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company’s stock valued at $169,000 after buying an additional 579 shares during the last quarter. GW Henssler & Associates Ltd. acquired a new position in shares of InMode during the third quarter valued at $177,000. Finally, DGS Capital Management LLC bought a new position in shares of InMode during the third quarter worth about $182,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Stock Down 1.3 %

Shares of INMD opened at $18.81 on Monday. The firm has a market capitalization of $1.31 billion, a PE ratio of 8.00 and a beta of 2.13. The firm has a 50-day moving average price of $17.35 and a 200 day moving average price of $17.24. InMode Ltd. has a 52-week low of $14.87 and a 52-week high of $24.03.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on INMD shares. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research report on Tuesday, February 4th. Barclays lifted their price target on InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $22.25.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.